Rationale:
Chronic subdural hematoma (CSDH) is a common condition encountered by neurologists and
neurosurgeons. While guidelines for the management of CSDH have recently been developed,
high-quality evidence to inform these recommendations, particularly level I evidence from
randomized clinical trials (RCTs), is awaited. Significant variability in the management
of CSDH persists at international, national, and inter-hospital levels. To further refine
and implement evidence-based guidelines, a detailed understanding of current clinical
practices and their associated outcomes is essential.
Objective:
To describe the baseline characteristics, treatment strategies, and outcomes of patients
diagnosed with chronic subdural hematoma.
Study design:
A prospective, observational multicenter cohort study.
Study population:
All adult patients diagnosed with chronic subdural hematoma.
Main study parameters/endpoints:
The primary endpoint is functional outcome, measured by the modified Rankin Scale (mRS)
at 3 months. Secondary endpoints, also assessed at 3 months, include recurrence,
mortality, complications, hospital length of stay, Markwalder Grading Scale (MGS),
modified National Institutes of Health Stroke Scale (mNIHSS), and Telephone Interview for
Cognitive Status (TICS).
Nature and extent of the burden and risks associated with participation, benefit and
group relatedness:
Patients will be treated in accordance with standard clinical practice. Study
participation imposes minimal additional burden, consisting of a single telephone
interview at three months, estimated to take approximately 10 minutes. The findings from
this registry are expected to benefit future CSDH patients by informing evidence-based
guidelines and improving care practices.